Treatment For Diabetic Macular Edema - Results From The Six-Month Interim Readout Of The Human PK Iluvien Study
Oct 3rd 2008Drug InformationClinical Trials
Drug delivery company, pSivida Corp. (NASDAQ: PSDV)(ASX: PVA)(FF: PV3), together with its licensing and development partner, Alimera Sciences, have today reported the interim six-month safety and efficacy results from the first human pharmacokinetici (PK) study of Medidur? FA, which will be marketed under the trade name Iluvien?, if approved by the U.S. Food and Drug Administration.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
